Mabura 40mg

Mabura 40mg Adalimumab 40mg Injection is a medication used to treat:

• Rheumatoid Arthritis (RA): a chronic autoimmune disease that causes inflammation, stiffness, and pain in the joints
• Psoriatic Arthritis (PsA): a chronic autoimmune disease that causes inflammation, stiffness, and pain in the joints, as well as skin and nail symptoms
• Crohn’s Disease and Ulcerative Colitis: inflammatory bowel diseases that cause inflammation and damage in the digestive tract

Composition: Each vial of Mabura contains 40mg of Adalimumab (an active pharmaceutical ingredient), a tumor necrosis factor (TNF)-alpha inhibitor.

Mechanism of Action: Adalimumab works by:

• Binding to TNF-alpha, a protein that promotes inflammation and tissue damage
• Neutralizing the activity of TNF-alpha, which reduces inflammation and tissue damage
• Inhibiting the production of pro-inflammatory cytokines and chemokines

Dosage: The recommended dose of Mabura is:

• 40mg every other week, injected subcutaneously (under the skin)
• The dose should be adjusted according to patient response and tolerance

Side Effects: Common side effects of Mabura include:

• Injection site reactions (e.g. redness, swelling, itching)
• Headache
• Fatigue
• Diarrhea
• Nausea or vomiting
• Rash or itching

Rare but serious side effects include:

• Serious infections (e.g. tuberculosis, bacterial sepsis)
• Cancer
• Autoimmune disorders (e.g. lupus-like syndrome)
• Neurological problems (e.g. multiple sclerosis-like syndrome)

Recommendation: Mabura is recommended for patients who have not responded to other treatments or who have had unacceptable side effects. Patients with active infections, cancer, or a history of tuberculosis should be closely monitored while taking Mabura.

Important Note:

• Mabura should be used under the guidance of a healthcare provider with experience in the treatment of RA, PsA, Crohn’s Disease, or Ulcerative Colitis.
• Patients should be advised to report any symptoms of hypersensitivity reactions, such as rash, itching, swelling, or difficulty breathing.
• Mabura may interact with other medications, such as antibiotics or immunosuppressants. Patients should inform their healthcare provider of all medications they are taking before starting Mabura therapy.
• Patients with a history of kidney disease or other medical conditions that may affect their ability to respond to treatment should be closely monitored while taking Mabura.

Special Precautions:

• Patients with active infections should be closely monitored while taking Mabura.
• Patients with a history of tuberculosis should be evaluated for active tuberculosis before starting Mabura therapy.
• Pregnant or breastfeeding women should consult their healthcare provider before taking Mabura.
• Patients with a history of cancer should be closely monitored while taking Mabura.

Indications:

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Crohn’s Disease
• Ulcerative Colitis

Contraindications:

• Active tuberculosis
• Severe infections
• Cancer
• Pregnancy and breastfeeding (unless medically necessary)

Note: The above information is a general summary and is not intended to provide individualized advice or recommendations. It is always best to consult a healthcare provider for personalized guidance on the use of Mabura 40mg Adalimumab 40mg Injection.